Ananda Pharma
Simply days after welcoming the previous Chief Working Officer of GW and Jazz Prescribed drugs to its ranks Ananda has introduced its entrance onto the US OTCQB Trade, opening up its inventory to US traders.
In accordance with the corporate, its major itemizing will stay the Apex phase of the Aquis Inventory Trade, however its twin itemizing will present ‘simpler cross-border buying and selling for potential US traders’, and open the corporate as much as a lot better liquidity.
There is no such thing as a related capital increase with its new itemizing, which went stay on April 14 at 2.30 pm (London time) underneath the ticker ‘ANANF’ for a nominal worth of £0.002 every.
This, based on its CEO Melissa Sturgess, represents the third step in its technique to interrupt into the US.
Step one on this three-pronged method was the appointment of US hashish funding and monetary providers agency Viridian Capital Advisors in February of this 12 months, adopted by the current appointment of Chris Tovey, who performed a key position in launching Epidyolex throughout the globe.
“As we begin our world-leading cannabinoid medical trials into a variety of advanced persistent circumstances, we’re targeted on the US as the important thing marketplace for commercialising future regulatory-approved medicines. Growing our visibility on this market is an important step and one I’m happy we’re making,” Sturgess continued.
Argent Biopharma
Argent Biopharma has managed to retain the majority of the positive aspects in inventory worth it gained earlier this month following information that it had gained approval to interrupt into the German market.
This week, the ASX-listed hashish drug-developer introduced a brand new strategic ‘heads of settlement’ with Australia’s AusCann Group Holdings.
Whereas nonetheless within the preliminary, non-binding levels, the settlement would allow AusCann to licence key knowledge on Argent’s proprietary CBD-based refractory epilepsy remedy, CannEpil.
AusCann will probably be given entry to the chemistry, manufacturing and controls (CMC) and regulatory file to be used in ‘non-epilepsy pharmaceutical applications’, geared toward accelerating analysis into its potential functions for remedy of different circumstances.
A CMC usually gives complete technical details about the drug substance and drug product, together with how it’s made, examined, and managed to make sure security, high quality, and consistency.
In return, Argent will probably be given entry to pharmacokinetic and pharmacodynamic knowledge from AusCann’s Neuvis formulation, a self-emulsifying hard-shell capsule which has reportedly proven improved stability, bioavailability, and scalability, with the information anticipated to assist regulatory submissions and growth methods.
To coordinate analysis and growth actions between the 2 firms and their respective merchandise, a joint steering committee will probably be established.
Moreover, a deferred licensing price construction and royalties on future pharmaceutical merchandise developed utilizing shared belongings will probably be put in place.
Argent Chairman Roby Zomer described the settlement as ‘a serious validation’ of the corporate’s funding in CannEpil, including that the licensing association permits Argent to generate new income streams whereas preserving its epilepsy franchise.
IM Hashish
Israeli medical hashish operator IM Hashish is dealing with delisting from the NASDAQ for a 3rd time since 2022, after receiving a warning that it was not in compliance with stockholders’ fairness itemizing necessities.
On April 09, 2025, the corporate reported stockholders’ fairness (the worth of an organization’s complete belongings minus its complete liabilities) of US$2.18m, under the minimal requirement of $2.5m.
Moreover, the change famous that IMC not met the choice standards for market worth of listed securities or internet revenue from persevering with operations.
As such, IMC now has 45 days (till Could 26) to submit a plan to regain compliance. If that is accepted, it might be given an extra 180 days to regain compliance with these a number of guidelines.
This isn’t the primary time the corporate has been in breach of the minimal necessities on NASDAQ, first receiving a warning for being under the minimal share worth requirement of $1 in July 2022, then once more in August 2023.
In accordance with IMC, the notification has ‘no instant impact’ on its itemizing or enterprise operations.
In the meantime, IMC is within the means of absolutely buying Focus Medical Herbs, an Israeli firm beforehand concerned in hashish cultivation and now targeted on importing medical hashish.
IMC already owns 74% of Focus and has introduced plans to amass the remaining 26% from Ewave Group, an organization owned by two people who’re associated events to IMC.
The agreed worth of the 26% stake is NIS 818,740 (roughly US $220,000), which will probably be paid in newly points IMC widespread shares.
